{"url_path":"/sec/eltx/8-k/2026-06-15/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000046-index.html","accession_number":"0001601485-26-000046","cik":"0001601485","ticker":"ELTX","issuer_name":"Elicio Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000046-index.html","primary_entity_key":"0001601485","primary_entity_name":"Elicio Therapeutics, Inc."},"word_count":90,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn June 15, 2026, Elicio Therapeutics, Inc. (the “Company”) issued a press release announcing the results from the Company’s randomized Phase 2 AMPLIFY-7P study in adjuvant mutant KRAS-driven pancreatic ductal adenocarcinoma and outlining the Company’s refined Phase 3 development strategy for ELI-002 7P. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference. Attached as Exhibit 99.2 and incorporated by reference is the Company’s conference call presentation of the Phase 2 AMPLIFY-7P results."}